Navigation Links
Immunotherapy Offers New Hope for Cancer Patients: One Man’s Alternative Cancer Treatment Journey
Date:12/23/2013

Simpsonville, SC (PRWEB) December 23, 2013

It started as a mole on his leg, and spread quickly, despite aggressive chemotherapy and surgery. When 59-year-old Ray Merrill learned his melanoma was incurable and amputation of his leg was the only option available to buy just a little more time, he prayed for another solution. The alternative cancer treatment he found at Perseus PCI earlier this fall was literally the answer to his prayers, keeping his limb intact while bringing him immediate relief from pain, and in December, an extensive imaging test showed came back clear, showing no evidence of disease.

“My oncologist couldn’t believe it!” marvels Merrill. “Just a few months ago, I was headed straight to Stage 4 melanoma, with nothing but pain in the future. I was devastated, thinking I had no chance to see my 14-year-old daughter grow up.”

After receiving his ‘incurable’ diagnosis this fall, Merrill was determined not to spend whatever time he had left undergoing toxic chemotherapy regimens, or being bedridden after major surgery. Through his own extensive research and outreach, he learned of the Perseus PCI cancer vaccine.

“When I heard how it caused no side effects, I thought it was almost too easy to be real,” remembers Merrill. “Many people agreed with that conclusion and tried to talk me out of it, but I felt that this option was absolutely what I needed to do – it made sense and I was determined to try it. Hearing Dr. Wagner speak lifted my spirits and gave me hope, knowing there was a chance to beat this.”

Four months later, after completing the series of monthly inoculations, the soft-spoken Georgian native is certain his decision was the right, life-affirming one. From first to final treatment, all went smoothly, exactly as planned, and the most recent, completely clear PET (positron emission tomography) scan provided further evidence as to why Merrill feels better than he has in years.

With all the damage done by previous surgeries, including removal of lymph nodes, he had been in constant pain. The burning sensation on his legs made it difficult for him to function at his job as maintenance supervisor at a local eye center, or even sit for long periods of time. “Now I have my life back,” he reports. “The swelling on my leg is down, and the burning and pain is gone. I put in a full day at work, jog, ride my bike. My entire outlook has changed—I can now look forward to spending time with my daughter.”        

And while many hospitals and treatment centers work toward providing the ideal patient experience, Perseus actually delivers, according to Merrill. “I was treated like royalty,” says Merrill, “from the moment I stepped off the plane in the Cayman Islands. From the very beginning it was first class treatment, and everyone on staff was so knowledgeable and caring.”

After a simple blood draw, Merrill went back to the hotel to await his personalized immunotherapy vaccine. On the third day, he received his first injection of the serum, made from his blood and a small section of tumor taken from his biopsy sample. Then he flew home, feeling “absolutely fine, with not one side effect, not even the slight fever they warned me might happen.” Three subsequent visits at one-month intervals followed, and Merrill continued to recover as his skin healed and appetite and energy returned.

Already a veteran of chemotherapy used to treat the melanoma that had spread to his liver earlier this year, Merrill had endured its toxic effects firsthand. “I suffered through months where I couldn’t move, eat, or sleep, I was just a mess. If I had known about Perseus then, I wouldn’t have needed to go through that. That’s why I’m telling my story now, to try and help whoever I can.”

Says Dr. Thomas Wagner, the renowned biomedical scientist who created the Perseus cancer vaccine: “With patients like Ray, where the metastasis or spread of their tumor is still minimal, our vaccine can be very effective. It is my fervent hope that more patients will come to us at the earliest stage of their disease so we can see more and more dramatic recoveries like Ray’s.”

About the Perseus PCI Cancer Vaccine

The alternative cancer treatment was developed by Thomas Wagner, Ph.D., co-founder of Perseus PCI, a well-respected biomedical scientist and innovator responsible for pioneering some of the past half-century’s most important biomedical technologies. The Perseus PCI vaccine arms the immune system to destroy the tumor with the patient’s own T-cells, and creates a lifetime immunity to the disease. Approved by the Health Practice Commission of the Cayman Islands for research, the vaccine has gone through Phases I and II clinical trials in the U.S. for treatment of advanced stage melanoma, renal cell carcinoma and neuroblastoma. Additional trials of the immunotherapy treatment are being conducted in the U.S. and Europe through Orbis Health Solutions, LLC.

To learn more, visit http://www.perseuspci.com; or call 866-299-0750.

Read the full story at http://www.prweb.com/releases/2013/12/prweb11443939.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
2. Cancer Immunotherapy Expert Joins Pacific Meso Center Research Team
3. UroToday Launches New Prostate Cancer Focused Content Including Immunotherapy for Metastatic Castration-resistant Patients
4. Tuberculosis Immunotherapy Grant for Immunoxel Honibe Honey Lozenges
5. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
6. FDA Review in Journal for ImmunoTherapy of Cancer Offers New Insights into Cancer Immunotherapy Product Development & Clinical Evaluation
7. Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
8. Leading Cancer Research Centers Team Up To Launch Biotech Startup Focused On Cancer Immunotherapy
9. Fortis Offers Bachelor of Science in Nursing Degree Program to Florida Students
10. Gundersen Lutheran Offers Heart Surgery with Less Pain, Faster Recovery
11. UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , Jan. 23, 2017  Spherix Incorporated (Nasdaq: ... committed to the fostering of technology and monetization of ... patent infringement lawsuits. Anthony Hayes , ... 2017, we will continue to communicate with shareholders about ... and our due diligence on other patent assets that ...
(Date:1/23/2017)... CARLOS, Calif. , Jan. 23, 2017 /PRNewswire/ ... developing innovative treatments for neurodegenerative diseases and other ... has joined the company as Chief Medical Officer. ... translational and clinical development activities at Alkahest and ... Dr. Jackson most recently served as Executive Director ...
(Date:1/21/2017)... CA (PRWEB) , ... January 21, 2017 , ... ... our ongoing endeavors to bring to market a pioneering medical device for the ... has signed an engagement contract with Emergo, a global regulatory consultancy that helps ...
(Date:1/20/2017)... ... ... The two newest companies to join the University City Science Center’s Port business ... Wistar Institute, and Sanguis, launched by a trio of students from the University of ... developing a treatment for a chronic viral infection and its associated diseases, with the ...
Breaking Biology Technology:
(Date:12/20/2016)... Dec. 20, 2016 The rising popularity ... and leasing is stoking significant interest in keyless ... technology, Bluetooth low energy (BLE), biometrics and near-field ... next wave of wireless technologies in the automotive ... to advanced access systems opens the market to ...
(Date:12/19/2016)... , España y TORONTO , 19 de ... con Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, ... clínicos en varios tipos de tumor en 2017, con múltiples sitios ... ... su clase con objetivo en el factor inhibidor de leucemia (LIF), ...
(Date:12/16/2016)... Dec 16, 2016 Research and Markets has ... - Global Forecast to 2021" report to their offering. ... The biometric vehicle ... at a CAGR of 14.06% from 2016 to 2021. The market ... projected to reach 854.8 Million by 2021. The growth of the ...
Breaking Biology News(10 mins):